WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark VYGLXIA was filed as Word mark on 09/13/2021 at the World Intellectual Property Organization.
| Trademark form | Word mark |
| File reference | 1633064 |
| Countries | 
|
| Base trademark |
No. 90605911,
March 26, 2021
|
| Application date | September 13, 2021 |
| Expiration date | September 13, 2031 |
Trademark owner
Ritter House, P.O. Box 173,
Road Town
VG
Road Town
VG
Trademark representatives
1100 NEW YORK AVENUE, N.W.
WASHINGTON DC 20005
US
goods and services
05
Medicated and pharmaceutical preparations, both prescription
and over-the-counter, for use in connection with humans and
animals, namely, for the treatment of central nervous system
disorders, neurologic illnesses, and psychiatric illnesses;
pharmaceutical preparations for the treatment of brain
ischemia; pharmaceutical preparations for the treatment of
brain ischemia, namely, post-stroke recovery, severe
intracranial atherosclerosis, carotid endarterectomy,
cardiac bypass, cerebral vasculitis, reversible cerebral
vasoconstriction syndrome; pharmaceutical preparations for
the treatment of brain and cord injuries; pharmaceutical
preparations for the treatment of brain and cord injuries,
namely, post-intracranial hemorrhage recovery, traumatic
brain injury, spinal cord injury; pharmaceutical
preparations for the treatment of neurodegenerative
diseases; pharmaceutical preparations for the treatment of
neurodegenerative diseases, namely, Alzheimer's disease
(AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's
disease, Lewy body dementia, frontotemporal dementia,
vascular dementia, Parkinson's disease, cognitive impairment
of aging, progressive Multiple Sclerosis; pharmaceutical
preparations for the treatment of optic and retinal
neuropathies; pharmaceutical preparations for the treatment
of optic and retinal neuropathies, namely, glaucoma,
diabetic retinopathy, ischemic optic and retinal
neuropathies; pharmaceutical preparations for the treatment
of pain; pharmaceutical preparations for the treatment of
pain, namely, opioid sparing analgesia, chronic neuropathic
pain, peripheral neuropathy, low back pain in the nature of
failed back surgery syndrome, radiculopathy in the nature of
sciatica, diabetic peripheral neuropathy, post-herpetic
neuralgia, medication induced neuropathies, complex regional
pain syndrome, fibromyalgia, chronic post-operative pain,
cluster thoracotomy, phantom limb, stump neuroma;
pharmaceutical preparations for the treatment of headache
and facial pain, namely, headache, migraine, chronic daily
headache, cluster headache, trigeminal neuralgia;
pharmaceutical preparations for symptomatic treatments of
degenerative diseases; pharmaceutical preparations for
symptomatic treatments of degenerative diseases, namely,
breath holding in Rett syndrome, dystonias, dysphagia, gait
abnormalities, bulbar function in ALS, pseudobulbar affect,
levodopa-induced dyskinesias in Parkinson's disease,
agitation in AD, disinhibition in dementia; pharmaceutical
preparations for the treatment of epilepsy; pharmaceutical
preparations for the treatment of epilepsy, namely,
precision medicine - adjuvant for genetic epilepsy due to
NMDA receptor mutations with hyperactivation; pharmaceutical
preparations for the treatment of neuropsychiatric
disorders; pharmaceutical preparations for the treatment of
neuropsychiatric disorders, namely, treatment resistant
depression, Post Traumatic Stress Disorder (PTSD) in the
nature of hyperarousal, substance abuse disorders, addiction
disorders, Obsessive Compulsive Disorder (OCD), hoarding,
trichotillomania, eating disorders, Generalized Anxiety
Disorder (GAD), adjustment disorders, panic disorder, major
depressive episode, bipolar disorder in the nature of manic
and depressive episodes, dysthymia, cyclothymia, psychotic
disorders, schizophrenia; pharmaceutical preparations for
the treatment of cerebellar disorders; pharmaceutical
preparations for the treatment of cerebellar disorders,
namely, spinocerebellar ataxia, Friedriech's ataxia,
multisystem atrophy, essential tremor; pharmaceutical
preparations for the treatment of hearing disorders,
tinnitus, delirium, sleep disorders, parasomnias, learning
disorders, Attention Deficit Disorder (ADD), Pervasive
Developmental Disorders (PDD), Asperger's syndrome, autism,
menopausal hot flashes
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| June 1, 2023 | 2023/23 Gaz | IS | Rejection |
| April 17, 2023 | 2023/16 Gaz | KR | Rejection |
| March 28, 2023 | 2023/13 Gaz | CA | Rejection |
| December 28, 2022 | 2022/52 Gaz | NO | Rejection |
| December 9, 2022 | 2022/50 Gaz | LI | Rejection |
| December 4, 2022 | 2022/49 Gaz | IL | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| November 10, 2022 | 2022/45 Gaz | CH | Rejection |
| October 26, 2022 | 2022/43 Gaz | BR | Rejection |
| October 17, 2022 | 2022/42 Gaz | IN | Rejection |
| October 13, 2022 | 2022/41 Gaz | JP | Rejection |
| September 19, 2022 | 2022/50 Gaz | SG | Rejection |
| September 1, 2022 | 2022/35 Gaz | MX | Rejection |
| August 30, 2022 | 2022/35 Gaz | CO | Rejection |
| August 29, 2022 | 2022/35 Gaz | UA | Rejection |
| August 2, 2022 | 2022/31 Gaz | NZ | Rejection |
| May 16, 2022 | 2022/21 Gaz | IL | Rejection |
| May 6, 2022 | 2022/19 Gaz | EM | Rejection |
| April 19, 2022 | 2022/16 Gaz | CN | Rejection |
| April 5, 2022 | 2022/15 Gaz | PH | Rejection |
| April 1, 2022 | 2022/14 Gaz | TR | Rejection |
| March 21, 2022 | 2022/12 Gaz | GB | Rejection |
| March 16, 2022 | 2022/11 Gaz | AU | Rejection |
| March 14, 2022 | 2022/11 Gaz | RU | Rejection |
| February 24, 2022 | 2022/8 Gaz | MC | Rejection |
| September 13, 2021 | 2021/48 Gaz | US | Registration |
ID: 141633064